



Senate

General Assembly

File No. 28

February Session, 2026

Senate Bill No. 191

Senate, March 16, 2026

The Committee on Public Health reported through SEN. ANWAR of the 3rd Dist., Chairperson of the Committee on the part of the Senate, that the bill ought to pass.

AN ACT CONCERNING THE PSYCHEDELIC-ASSISTED THERAPY PILOT PROGRAM.

Be it enacted by the Senate and House of Representatives in General Assembly convened:

1 Section 1. Section 17a-484g of the general statutes is repealed and the
2 following is substituted in lieu thereof (*Effective July 1, 2026*):

3 (a) As used in this section:

4 (1) "MDMA" means the synthetic psychoactive drug, 3,4-
5 methylenedioxymethamphetamine, commonly known as ecstasy or
6 molly, that acts as a serotonin receptor agonist and reuptake inhibitor of
7 serotonin and dopamine.

8 (2) "Psilocybin" means a serotonin receptor agonist that occurs
9 naturally in some mushroom species.

10 (3) "Qualified patient" means an individual who is eighteen years of
11 age or older and meets clinical eligibility criteria established by the
12 institutional review board of the medical school selected to administer

13 the pilot program under subsection (b) of this section, including, but not
14 limited to, a resident of the state who is (A) a veteran, (B) a retired first
15 responder, or (C) a direct care health care worker.

16 (b) [Not later than January 1, 2023, the] The Department of Mental
17 Health and Addiction Services shall establish, within available
18 appropriations, a psychedelic-assisted therapy pilot program, to be
19 administered by a medical school in the state. Such pilot program shall
20 provide qualified patients with MDMA-assisted or psilocybin-assisted
21 therapy as part of a research program approved by the federal Food and
22 Drug Administration pursuant to 21 CFR 312, as amended from time to
23 time. [The department shall cease to operate the pilot program when
24 MDMA and psilocybin have been approved to have a medical use by
25 the Drug Enforcement Administration, or any successor agency.]

This act shall take effect as follows and shall amend the following sections:		
Section 1	July 1, 2026	17a-484g

PH *Joint Favorable*

The following Fiscal Impact Statement and Bill Analysis are prepared for the benefit of the members of the General Assembly, solely for purposes of information, summarization and explanation and do not represent the intent of the General Assembly or either chamber thereof for any purpose. In general, fiscal impacts are based upon a variety of informational sources, including the analyst's professional knowledge. Whenever applicable, agency data is consulted as part of the analysis, however final products do not necessarily reflect an assessment from any specific department.

OFA Fiscal Note

State Impact:

Agency Affected	Fund-Effect	FY 27 \$	FY 28 \$
Mental Health & Addiction Serv., Dept.	GF - Potential Cost	See Below	See Below

Note: GF=General Fund

Municipal Impact: None

Explanation

The bill results in a potential cost to the Department of Mental Health and Addiction Services (DMHAS) due to eliminating the requirement that DMHAS terminate the psychedelic-assisted therapy (PAT) pilot program when the federal Drug Enforcement Administration (DEA) approves MDMA and psilocybin for medical use. To the extent the pilot would have otherwise ended due to DEA approval, DMHAS may now continue to operate the pilot under the bill.

The bill also expands eligibility for the pilot, which may impact participant mix but does not require DMHAS to support additional clients.

The Out Years

The annualized ongoing fiscal impact identified above would continue into the future subject to federal DEA approvals.

OLR Bill Analysis**SB 191*****AN ACT CONCERNING THE PSYCHEDELIC-ASSISTED THERAPY PILOT PROGRAM.*****SUMMARY**

This bill expands eligibility for the Department of Mental Health and Addiction Services (DMHAS) psychedelic-assisted therapy (PAT) pilot program by allowing Connecticut residents to participate who (1) are at least age 18 and (2) meet clinical eligibility criteria established by the institutional review board of the medical school who administers it (currently Yale University). Currently, the pilot program is limited to Connecticut veterans, retired first responders, and direct health care workers. As under current law, participants must receive MDMA- (i.e. "Molly" or "ecstasy") or psilocybin-assisted therapy as part of a research program approved by the federal Food and Drug Administration (FDA).

The bill also eliminates the current requirement that DMHAS end the pilot program if the federal Drug Enforcement Agency (DEA) approves MDMA and psilocybin for medical use (the DEA has not yet done so).

MDMA is a synthetic psychoactive drug, and psilocybin occurs naturally in some mushrooms. Both act as serotonin receptor agonists, and MDMA also acts as a reuptake inhibitor of serotonin and dopamine.

EFFECTIVE DATE: July 1, 2026

COMMITTEE ACTION

Public Health Committee

Joint Favorable

Yea 23 Nay 8 (03/02/2026)